Glioblastoma — frontier options in Arizona
23 open options
- TRIALPHASE1 / PHASE2RECRUITING
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
TNG456 · abemaciclib — 15 sites
- TRIALPHASE4RECRUITING
Dabrafenib and/or Trametinib Rollover Study
dabrafenib · trametinib — 33 sites
- TRIALPHASE2RECRUITING
Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma
Bevacizumab · Biospecimen Collection · Computed Tomography — 3 sites
- TRIALPHASE2NOT_YET_RECRUITING
Temozolomide, With or Without WSD0922-FU, for the Treatment of EGFR-Mutant, IDH-Wildtype Glioblastoma
Archive Sample Retrieval · Biospecimen Collection · Chest Radiography — 3 sites
- TRIALPHASE1 / PHASE2RECRUITING
A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
Biopsy Procedure · Magnetic Resonance Imaging · Radiation Therapy — 127 sites
- TRIALPHASE3RECRUITING
Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM
SonoCloud-9 (SC9) · Carboplatin · Lomustine — 55 sites
- TRIALPHASE1 / PHASE2RECRUITING
Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
Tarlatamab · Concurrent Radiation Therapy · Sequential Radiation therapy — 2 sites
- TRIALNARECRUITING
Continuous Glucose Monitoring for the Management of Hyperglycemia in Patients With Glioblastoma
Best Practice · Biospecimen Collection · Dietary Intervention — 3 sites
- TRIALPHASE2RECRUITING
DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)
DOC1021 · Tumor resection · Temodar (Temozolomide) — 18 sites
- TRIALEARLY_PHASE1NOT_YET_RECRUITING
A Phase 0/1 Study of NST-628 in Recurrent Grade 4 Glioma
NST-628 — 1 site
- TRIALPHASE1RECRUITING
Preoperative Radiosurgery for the Treatment of High Grade Glioma, NeoGlioma Trial
Radiation Therapy · Radiosurgery · Stereotactic Biopsy — 2 sites
- TRIALEARLY_PHASE1RECRUITING
Clinical Trial of BMS-986504 in Recurrent GBM Patients
BMS-986504 — 1 site
- TRIALNARECRUITING
Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Glioblastoma
Device :DaRT seeds — 3 sites
- TRIALEARLY_PHASE1RECRUITING
A Phase 0/1 Study of BDTX-1535 in Recurrent High-Grade Glioma (rHGG) and Newly Diagnosed Glioblastoma (nGBM) Participants With EGFR Alterations or Fusions
BDTX-1535 · BDTX-1535 combined with radiation therapy · BDTX-1535 combined with temozolomide and radiation therapy — 2 sites
- TRIALPHASE1 / PHASE2RECRUITING
Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
Biospecimen Collection · Magnetic Resonance Imaging · Placebo Administration — 36 sites
- TRIALPHASE1RECRUITING
Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma.
Anti-B7-H3 Chimeric Antigen Receptor T-Cell (CAR-T Cell) Injection/TX103 — 4 sites
- TRIALPHASE1 / PHASE2RECRUITING
A Phase 1/2 Study of the Safety and Tolerability of MT-125 in GBM Patients
MT-125 — 3 sites
- TRIALPHASE1 / PHASE2NOT_YET_RECRUITING
A Phase 1/2 Study of Safety and Tolerability of MT-125 With Chemoradiation in Patients With Newly Diagnosed MGMT Methylated Glioblastoma
MT-125 — 3 sites
- TRIALPHASE3RECRUITING
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
Optune® device · Temozolomide · Pembrolizumab — 102 sites
- TRIALEARLY_PHASE1RECRUITING
BGB-58067 in Newly Diagnosed Glioblastoma Patients With MTAP-Deleted Tumors
BGB-58067 — 1 site
- TRIALPHASE3RECRUITING
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
safusidenib · Placebo — 57 sites
- TRIALPHASE3RECRUITING
Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care
GammaTile® · External Beam Radiation Therapy · Temozolomide — 7 sites
- TRIALEARLY_PHASE1RECRUITING
A Phase 0/1 Clinical Trial With an Expansion Phase of GSK5764227, a B7-H3-Targeted Antibody-Drug Conjugate (ADC), in Patients With Recurrent Grade 4 Glioma and Patients With Brain Metastases
Risvutatug rezetecan — 1 site
Live from ClinicalTrials.gov, refreshed at most hourly · registry query ↗
Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors.